GHR rs6873545: Understanding the Exon 3 Deletion Variant
The rs6873545 variant serves as a tagging SNP for a common genomic deletion of exon 3 in the growth hormone receptor (GHR) gene. This variant is associated with differences in how the body responds to growth hormone and has been studied for its potential links to insulin sensitivity and longevity.
What each genotype means
Enhanced growth hormone signaling
This genotype is associated with the d3-GHR isoform, which lacks exon 3 and has been linked to enhanced growth hormone signaling within cells. Some research suggests this variant may be associated with improved insulin sensitivity and potentially increased longevity in males, though evidence remains limited. If you are undergoing growth hormone therapy, discuss the potential for an altered growth response with your clinician.
This genotype is found in a significant portion of the population, with the C allele occurring at a frequency of approximately 0.26 to 0.30 in European cohorts.
Mixed growth hormone receptor profile
This genotype indicates you carry one copy of the full-length GHR gene and one copy of the d3-GHR variant. You possess both the full-length and exon 3-deficient isoforms of the growth hormone receptor. Research into the functional impact of this heterozygous state is ongoing, and you should consult with a healthcare provider regarding any specific clinical implications for your health or medical treatments.
This is a common heterozygous genotype observed frequently in diverse populations alongside the homozygous states.
Standard growth hormone receptor profile
This genotype corresponds to the full-length GHR isoform, which is considered the common or standard form of the receptor. This version of the receptor functions normally in the growth hormone/IGF-I axis. No specific health risks or advantages are definitively linked to this genotype in the general population.
This is the most common genotype for this variant in most studied populations, representing the majority of individuals.
What is the rs6873545 Variant?
The rs6873545 variant is a genetic marker located within the GHR gene, which provides instructions for making the growth hormone receptor. This receptor is essential for the body to process growth hormone, a substance that regulates growth, metabolism, and body composition. Specifically, rs6873545 acts as a proxy or 'tag' for a structural variation known as the d3-GHR polymorphism. This polymorphism involves the deletion of exon 3, a specific segment of the gene's DNA. Because this deletion is a structural change rather than a single-letter swap, researchers use SNPs like rs6873545 to identify which version of the receptor an individual carries. Understanding this variant is important because it helps scientists categorize individuals into those who produce the full-length receptor (fl-GHR) and those who produce the shorter, exon 3-deleted version (d3-GHR).
The Role of the Growth Hormone Receptor
The growth hormone receptor is found on the surface of many cell types throughout the body. When growth hormone binds to this receptor, it triggers a cascade of signals inside the cell that promote growth and regulate metabolic processes, such as the production of insulin-like growth factor 1 (IGF-1). The d3-GHR isoform, which lacks 22 amino acids compared to the full-length version, has been shown in laboratory studies to exhibit enhanced signaling capabilities. This means that cells carrying the d3-GHR receptor may be more sensitive to growth hormone stimulation. Because this receptor is a central player in the endocrine system, variations in its structure can influence how effectively the body utilizes growth hormone, which has implications for both clinical growth therapies and general metabolic health.
Research Associations and Evidence Strength
Research into the d3-GHR variant has primarily focused on pharmacogenetics—how genetics influence a patient's response to medication. Studies have consistently observed that children treated with recombinant human growth hormone often show a more robust growth response if they carry the d3-GHR isoform. Beyond growth, some research has explored links between this variant and metabolic health, including insulin sensitivity and even male-specific longevity. However, the evidence strength for these broader health associations remains limited. While some studies suggest a correlation with improved lifespan or metabolic outcomes, these findings are not universal across all populations and are often subject to debate. It is important to view these associations as statistical observations in specific cohorts rather than definitive predictors of individual health outcomes.
Population Frequency
The d3-GHR polymorphism is relatively common, with the exon 3 deletion allele appearing in a significant portion of the population. In European cohorts, the frequency of the deletion allele is approximately 0.26, meaning that many individuals carry at least one copy of this variant. Because individuals can be homozygous for the full-length receptor, heterozygous, or homozygous for the deletion, the distribution of these genotypes varies across different ethnic and geographic groups. While the deletion is widespread, its prevalence is not uniform, and researchers continue to study how these frequencies differ globally to better understand the evolutionary history and functional impact of the GHR gene.
Interpreting Your Genetic Information
If you have access to your genetic data regarding rs6873545, it is important to understand that this information is primarily used for research and population-level studies. While the variant is linked to differences in growth hormone sensitivity, it does not serve as a diagnostic tool for any medical condition. If you are currently undergoing growth hormone therapy or treatment for conditions like acromegaly, your clinical response is determined by a complex interplay of factors, including your overall health, hormone levels, and medical history. You should never use genetic information to make decisions about your medical care. Always discuss any questions regarding your treatment, medication dosing, or health status with your clinician or a qualified pharmacist who can provide context based on your specific clinical situation.
How common is this variant?
The d3-GHR deletion allele has a minor allele frequency of approximately 0.26 in European cohorts, with genotype distributions typically showing a majority of individuals carrying at least one full-length allele.
Frequently asked questions
Does the GHR exon 3 deletion affect my height?
While the d3-GHR variant is associated with increased sensitivity to growth hormone, it is not a primary determinant of adult height. Height is a complex trait influenced by hundreds of genetic variants and environmental factors.
Can I use this variant to predict my response to growth hormone therapy?
Research suggests that the d3-GHR variant may influence the magnitude of growth response in children receiving growth hormone therapy. However, this is a statistical observation, and your doctor will use clinical markers to monitor your specific response.
Is the d3-GHR variant linked to longevity?
Some studies have observed an association between the d3-GHR genotype and increased male longevity, potentially linked to metabolic benefits. This is an area of active research, and the evidence is currently considered limited.
Should I change my medication based on my GHR genotype?
No. You should never change your medication or dosing based on genetic test results. Always consult with your healthcare provider or pharmacist regarding any changes to your medical treatment.
Sources & further reading
Educational information only, last refreshed 10/13/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs6873545?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29